Picard Medical, Inc. · AMEX:PMI
Picard Medical — IPO Roadshow (July 2025)
22 slides from Picard Medical's IPO roadshow presentation, Jul 29, 2025
Slide 1: Picard Medical Inc.
Filed pursuant to Rule 433 of the Securities Act of 1933, as amended. Issuer Free Writing Prospectus dated July 29, 2025, relating to Preliminary Prospectus dated July 11, 2025, Registration No. 333-286295 Picard Medical Inc. Proposed NYSE American Ticker: PMI SynCardia's products are approved for s
Slide 2: Forward-Looking Statements
Forward-Looking Statements This Presentation contains statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can genera
Slide 3: Forward-Looking Statements
Forward-Looking Statements Neither the Company nor any of its subsidiaries, affiliates, representatives or advisors assumes any responsibility for or makes any representation or warranty (express or implied) as to, the reasonableness, completeness, accuracy or reliability of the estimates and inform
Slide 4: The Initial Public Offering Summary
The Initial Public Offering Summary Issuer Picard Medical, Inc. Proposed Exchange NYSE American Proposed Ticker PMI Proposed IPO date August 2025 Proposed Price Range $3.50 to $4.50 Outstanding Shares prior to Offer 68,074,145 Share Type Common Stock Offering Shares 4,250,0001 Outstanding Shares aft
Slide 5: Use of Proceeds
Use of Proceeds1 Category Amount Purpose R&D, Product Development ~$2.96M • R&D for our fully implantable system including early feasibility animal trials and additional design and engineering changes Sales & Marketing ~$0.50M • Expand sales, marketing, and distribution capabilities & support invent
Slide 6: Driving Scalable Growth with an Experienced, Results-Focused Team
Driving Scalable Growth with an Experienced, Results-Focused Team Patrick has 25 years of executive Matt was appointed Chief Operating Bernard was appointed Chief Financial leadership in the medical device sector Officer in November 2023. He Officer in November 2023. He brings and was appointed CEO
Slide 7: SynCardia At-a-Glance
SynCardia At-a-Glance Market Leader: Global innovator in total artificial heart technology and a wholly owned subsidiary of Picard Medical, Inc. (Proposed NYSE American Ticker: PMI). Only FDA-Approved TAH: The SynCardia Total Artificial Heart (“STAH”) is the only commercially available total artific
Slide 8: Our Mission
To pioneer the future of heart replacement by providing the Our Mission world’s first Total Artificial Heart and developing the next- generation system as an alternative to transplantation SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owne
Slide 9: The Problem: Shortage of Donor Hearts Leaves Thousands Waiting
The Problem: Shortage of Donor Hearts Leaves Thousands Waiting Demand for Donor Hearts Unmet Need: Exceeds Supply1 Significant Demand-Supply Imbalance With up to 300,000 Patients in Need of a Solution 7,500+ 4,000+ Patients Waiting on Heart Patients Added to Heart Transplant List Transplant Waiting
Slide 10: The Solution: The First FDA Approved Total Artificial Heart
The Solution: The First FDA Approved Total Artificial Heart — Designed for Hospital and Home Use Total Artificial C2 Driver for Use in Freedom Driver for Heart Hospital Home Use The STAH is intended to replace a failing or failed human heart in patients with advanced stage heart failure and in need
Slide 11: 20 Years of Leadership: From First FDA Approval to Future Innovation
20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts 2004 Patient Hospitalized FDA approves 70cc STAH 2012 Patient Mobile in Hospital FDA approves Companion C2 Driver 2014 Patient Mobile in Home FDA approves First company to Freedom Driver 2
Slide 12: Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage
Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage With Over 2,100 STAH Implants Survival Rate to transplantation (vs. 79% 46% in control group)1 Survival Rate at one year (vs. 31% in 70% control group)1 Survival Rate at one year after heart 75% transplant2 Over 2,100 S
Slide 13: Utilized by High Volume Transplant Centers Across the U.S. and Europe
Utilized by High Volume Transplant Centers Across the U.S. and Europe The First and Only Commercially Available Total Artificial Heart in the U.S. & Canada Centers of Excellence1 High Volume U.S. and European Hospitals are Using SynCardia (1) Center of Excellence (CoE): A high-standard transplant /
Slide 14: Lev'Veon's Story: Courage, Innovation, and a Lifesaving First
Lev’Veon’s Story: Courage, Innovation, and a Lifesaving First Age: 10 years old Diagnosis: Myocarditis Implanted: September 6, 2024 Transplanted: September 30, 2024 24 days of Support on the STAH Mott Children’s Hospital First STAH Implant Sources: Mott Children’s Hospital & SynCardia Systems, LLC S
Slide 15: From Implant to Advocacy: Empowering Lives with the STAH
From Implant to Advocacy: Empowering Lives with the STAH Extending Lifespan and Enhancing Quality of Life Johnny is now the co-founder and CEO of Unique Beating Hearts • Unique Beating Hearts is a compassionate non-profit organization headquartered in California. • Provides group counseling assistan
Slide 16: STAH Growth Trajectory: Regional Mix and Sales 2022–2024
STAH Growth Trajectory: Regional Mix and Sales 2022–2024 STAH Sales (Units) by Region vs. Revenues ($MM) 2022 to 2024 30 $6 $5.0MM 25 $4.4MM $5 $3.7MM 20 $4 Revenues $MM STAH Units 15 $3 10 $2 5 $1 - $0 2022 2023 2024 US & Canada Europe ROW (1) Revenues (1) Rest of World Source: SynCardia Systems, L
Slide 17: Near-Term Growth Drivers: Site Expansion, Education, Enhancing Access and Reimbursement
Near-Term Growth Drivers: Site Expansion, Education, Enhancing Access and Reimbursement Protect existing transplant Grow social media 05 01 centers; grow and acquire presence new centers Increase publications submissions, Launch web-based congress attendance education and training 06 02 portal Impro
Slide 18: Mid-Term Growth Drivers: Label Expansion and Approvals
Mid-Term Growth Drivers: Label Expansion and Approvals Set to Fuel U.S. and Global Commercial Momentum Updated BTC Label (Expected 2Q26) MDR CE-Mark (Expected 4Q26) NMPA Approval (Expected 4Q26) Emperor Approval (Expected 2028) Currently selling under derogation/ SynCardia Medical Beijing will produ
Slide 19: Long-Term Market Growth: Driven by R&D Pipeline and IP-Backed Innovation
Long-Term Market Growth: Driven by R&D Pipeline and IP-Backed Innovation Platform / Product 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 May Seek FDA Approval of Fully Implantable STAH (Emperor) May Seek FDA Approval of Next Generation Pneumatic Technology Driver (Unicorn) Patents Covering Next Generatio
Slide 20: Decades of Clinical Leadership in BTT Patients: Outpaces Emerging Competitors
Decades of Clinical Leadership in BTT Patients: SynCardia’s Total Artificial Heart Outpaces Emerging Competitors SynCardia Carmat BiVACOR® Total Artificial Heart™ Aeson® TAH Regulatory Status (US & Approved Not approved (US EFS being restarted) Not approved (US EFS in progress) Canada) Regulatory St
Slide 21: Investment Drivers: Validated, Protected and Positioned for Growth
Investment Drivers: Validated, Protected and Positioned for Growth Leader in High- Addresses Most Market Competitive Strong Expected Reimbursed Demand Market Severe Patients Validation Advantage Sales Growth We believe Implantation with Over 2,100 STAH We believe STAH is reimbursed We believe near-,
Slide 22: THANK YOU
SynCardia Systems, LLC 1992 E. Silverlake Rd. Tucson, AZ 85713 | US +1 520-545-1234 | info@syncardia.com www.SynCardia.com Addresses Most Severe Patients THANK YOU Delivering Proven Outcomes in the SynCardia Systems, LLC – a Picard Medical Company The STAH is approved for sale in the US and in Canad